Innovent, Hutchmed announce conditional approval for cancer drug combination therapy
Innovent Biologics and Hutchmed (china) limited have received conditional nmpa approval for the combination therapy of tyvyt (sintilimab injection) and elunate (fruquintinib) for treating advanced ... Read More